- VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”).
- Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites.
- The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute.
- VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb.
- The company reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, alongside additional pending applications.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element of its approach.
The latest pipeline development involves VXA-222, a bispecific antibody-drug conjugate that has moved beyond the initial discovery phase following the completion of VERAXA’s collaboration with OmniAb. VERAXA is now responsible for engineering the final therapeutic candidate using antibody binders generated through the collaboration, followed by preclinical validation.
The program illustrates how VERAXA is applying its antibody-engineering capabilities beyond its BiTAC platform. VXA-222 is not itself a BiTAC candidate, but incorporates the company’s expertise in antibody engineering, linker technologies and conjugation.
The broader strategy is important because ADCs have become one of the most closely watched areas of oncology drug development. An ADC combines an antibody designed to recognize a cancer-associated target with a potent therapeutic payload. The objective is to direct that payload toward tumor cells while limiting exposure elsewhere in the body.
Bispecific ADCs extend that concept by recognizing two targets. VERAXA’s VXA-222 program is designed around this dual-targeting principle, with the intention of increasing tumor selectivity by requiring recognition of two tumor-associated antigens.
The company’s more distinctive approach is BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity. Rather than simply placing two targeting functions into one conventional bispecific molecule, VERAXA separates the therapeutic mechanism into complementary components.
The underlying concept is an “AND gate.” Therapeutic activity is intended to become functional when both components encounter the appropriate targets on the same cancer cell. The company believes this could help distinguish tumor cells carrying both markers from healthy cells carrying only one.
That distinction addresses one of the persistent challenges in antibody-based oncology: on-target, off-tumor toxicity. A cancer-associated antigen may also occur on healthy tissue, meaning that targeting the antigen alone can limit the dose that can safely be administered. By requiring two biological signals, VERAXA is attempting to make tumor recognition more selective.
The company has generated early experimental data supporting the concept. At the 2026 American Association for Cancer Research Annual Meeting, VERAXA reported that its lead BiTAC-TCE candidate attacked cells displaying both target molecules while sparing cells expressing only one. The company said the candidate demonstrated matching efficacy and a superior safety profile compared with a conventional TCE in the reported studies.
BiTAC is being applied to both TCEs and ADCs. In a BiTAC-TCE, separate components are designed to establish T-cell-engaging activity only after the required tumor targets are encountered. In a BiTAC-ADC, VERAXA is pursuing a different implementation in which complementary components enable selective activation of a cytotoxic payload inside targeted tumor cells.
The company reported proof-of-concept data for its BiTAC-ADC platform in June. In vitro experiments showed discrimination between breast cancer and healthy cells and dose-dependent killing of three-dimensional tumor spheroids.
The development program is now moving closer to the regulatory-development stage. In July, VERAXA announced that it had initiated cell-line development with ATUM for its lead BiTAC-TCE program, supporting planned IND/CTA-enabling activities. VERAXA subsequently received Scientific Advice from Germany’s Paul-Ehrlich-Institute concerning the biological rationale and proposed non-clinical development plan for the program.
The company is also using computational tools to support its pipeline. In July, VERAXA announced a collaboration with Ardigen intended to apply artificial intelligence and bioinformatics to the selection of cancer target pairs for future BiTAC-TCE and BiTAC-ADC candidates.
Intellectual property is another component of the strategy. VERAXA said in late July that it had filed its first patent applications specifically covering its newer BiTAC-TCE and BiTAC-ADC platforms, while previously granted patents covering supporting technologies had cleared opposition periods. The company reported more than 50 granted owned or exclusively licensed patents spanning 26 patent families in 14 countries. VERAXA said pending applications are expected, if granted, to extend protection for portions of its core technology portfolio through at least 2047.
The portfolio also extends beyond BiTAC. VERAXA has additional ADC programs and VXA-901, an Fc-enhanced FLT3-targeting monoclonal antibody for acute myeloid leukemia. The company has indicated that certain assets are available for partnering as it concentrates resources on its newer platform technologies.
The company became publicly traded on NASDAQ in June 2026, following completion of its business combination with Voyager Acquisition Corp. The transaction was accompanied by a $27.5 million senior secured note and a securities purchase agreement providing for up to $50 million to support development of its pipeline.
For more information, visit the company’s website at www.Veraxa.com.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
